MC-Val-Cit-PAB-dimethylDNA31 has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Val-Cit-PAB-dimethylDNA31 is used for the antibody-drug conjugates (ADC) that are effective and stable in vitro and in vivo to treat various diseases or disorders.
Structure of 1639352-06-9
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
MC-Val-Cit-PAB-dimethylDNA31 is a specialized conjugate designed to deliver the potent nucleic acid-modifying agent dimethylDNA31 to specific cellular targets. DimethylDNA31, a modified DNA analog, has been studied for its ability to modulate gene expression and interfere with cellular processes by interacting with the DNA. By linking dimethylDNA31 to a peptide through the MC-Val-Cit-PAB linker, this conjugate facilitates the targeted delivery of the DNA-modifying agent to cells or tissues that express specific biomarkers, improving the therapeutic efficacy while minimizing side effects. This approach opens up new possibilities for targeted genetic therapies and gene regulation.
One of the key applications of MC-Val-Cit-PAB-dimethylDNA31 is in gene therapy, where it can be used to deliver genetic regulators directly to specific tissues or cells. Traditional gene therapy approaches often suffer from low specificity and off-target effects, which can lead to unwanted consequences in healthy tissues. The MC-Val-Cit-PAB linker in this conjugate enables the selective targeting of cells or tissues expressing particular receptors or biomarkers, ensuring that dimethylDNA31 is delivered directly to the desired site. This enhances the precision of genetic interventions, improving the outcomes of gene therapy while reducing potential side effects.
MC-Val-Cit-PAB-dimethylDNA31 also has potential applications in cancer therapy, especially in cancers where specific genetic mutations or overexpressed proteins drive tumorigenesis. By attaching dimethylDNA31 to a targeting peptide, the conjugate can deliver the DNA-modifying agent specifically to cancer cells that overexpress certain receptors. Once inside the tumor cells, dimethylDNA31 can modify the DNA or influence gene expression, potentially disrupting key oncogenic pathways. This targeted approach may offer a more effective and less toxic alternative to conventional cancer therapies.
In addition to gene and cancer therapies, MC-Val-Cit-PAB-dimethylDNA31 could be useful in drug discovery and research. By selectively delivering dimethylDNA31 to specific cell types or tissues, researchers can study its effects on gene expression, DNA repair mechanisms, and cellular processes. This conjugate could serve as a tool for investigating the roles of specific genes in various biological functions, as well as for screening potential drug candidates that can modulate DNA-related pathways. Its ability to target precise cellular locations allows for more controlled experimental conditions and more accurate results in research settings.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00968 | MC-Val-Cit-PAB | 159857-80-4 | |
BADC-00501 | Mc-Val-Cit-PABC-PNP | 159857-81-5 | |
BADC-01745 | MC-Val-Cit-PAB-NH-C2-NH-Boc | 1616727-22-0 | |
BADC-00610 | Mc-Val-Cit-PAB-Cl | 1639351-92-0 | |
BADC-00611 | MC-Val-Cit-PAB-clindamycin | 1639793-13-7 | |
BADC-00612 | MC-Val-Cit-PAB-Retapamulin | 1639793-15-9 | |
BADC-00629 | MC-Val-Cit-PAB-Auristatin E | 2055896-77-8 | |
BADC-00630 | MC-Val-Cit-PAB-carfilzomib | 2055896-83-6 | |
BADC-00631 | MC-Val-Cit-PAB-tubulysin5a | 2055896-86-9 | |
BADC-00857 | MC-Val-Cit-PAB-vinblastine | 2055896-92-7 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.